Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Antimicrobial agents and chemotherapy - 1 Sept 2003

Bemer Pascale, Juvin Marie-Emmanuelle, Bryskier Andre, Drugeon Henri

Abstract excerpt

The purpose of this study was to compare the activity of HMR 1043 with those of daptomycin and teicoplanin against gram-positive isolates. Susceptibility tests were performed for 52 strains, 26 parental strains, including staphylococcal, streptococcal, enterococcal, and listerial strains, and 26 HMR 1043-resistant mutants obtained from parental strains by using the Szybalski method. Agar dilution and disk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Calcium
Share to Diffusion

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Gram-Positive Bacteria

Share to Lipopeptides

Share to Microbial Sensitivity Tests

Share to Peptides, Cyclic

Source

Open in PubMed Open full text

Identifiers

PMID: 12937020
DOI: 10.1128/AAC.47.9.3025-3029.2003
PMCID: PMC182620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.PMID 12937020Read ↗

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensSemantic proximity Read ↗

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Semantic proximity Read ↗

Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound.Semantic proximity Read ↗

In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp.Semantic proximity Read ↗

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococciSemantic proximity Read ↗

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.Semantic proximity Read ↗

In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.Semantic proximity Read ↗

In-vitro activity of two glycylcyclines against enterococci resistant to other agents.Semantic proximity Read ↗

Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.